Patent search ap:("Novartis AG") AND inv:"Thomas Huber" Page 1

1.

发明授权
CKIT antibody drug conjugates 有权

公开(公告)号：US10786578B2

公开(公告)日：2020-09-29

申请号：US15329818

申请日：2015-07-27

Applicant: Novartis AG

Inventor： Tinya Abrams , Steven Bruce Cohen , Dylan Daniel , Catrin Finner , Bernhard Hubert Geierstanger , Thomas Huber , William Mallet , Matthew John Meyer , Weijia Ou , Siew Ho Schleyer , Kathrin Ulrike Tissot-Daguette

IPC: A61K39/00 , A61K47/68 , C07K16/28 , A61K51/10 , A61K49/00 , A61P35/02 , A61K39/395

Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

2.

发明申请
TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR 审中-公开

公开(公告)号：US20180044423A1

公开(公告)日：2018-02-15

申请号：US15689163

申请日：2017-08-29

Applicant: Novartis AG , The Trustees of the University of Pennsylvania

Inventor： Hilmar Erhard Ebersbach , Thomas Huber , Julia Jascur , Celeste Richardson , Reshma Singh , Huijuan Song , Qilong Wu , Jiquan Zhang

IPC: C07K16/28 , A61K31/711 , A61K35/28 , A61K38/17 , A61K39/395 , A61K48/00 , C07K14/725 , A61K31/436 , C07K14/715 , C07K16/30 , C07K14/705 , A61K45/06 , A61K38/00 , A61K39/00

CPC classification number: C07K16/2851 , A61K31/436 , A61K31/711 , A61K35/28 , A61K38/00 , A61K38/1774 , A61K38/1793 , A61K39/39558 , A61K45/06 , A61K48/00 , A61K2039/505 , A61K2039/5156 , C07K14/7051 , C07K14/70517 , C07K14/7056 , C07K14/70578 , C07K14/7151 , C07K16/2803 , C07K16/30 , C07K16/3061 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/53 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2319/00 , C07K2319/03 , C07K2319/33 , C07K2319/70 , A61K2300/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.

3.

发明申请
ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF 有权
Title translation: 抗体分子到TIM-3及其用途

公开(公告)号：US20150218274A1

公开(公告)日：2015-08-06

申请号：US14610837

申请日：2015-01-30

Applicant: NOVARTIS AG , DANA-FARBER CANCER INSTITUTE, INC. , CHILDREN'S MEDICAL CENTER CORPORATION

Inventor： Catherine Anne Sabatos-Peyton , Barbara Brannetti , Alan S. Harris , Thomas Huber , Thomas Pietzonka , Jennifer Marie Mataraza , Walter A. Blattler , Daniel J. Hicklin , Maximiliano Vasquez , Rosemarie H. DeKruyff , Dale T. Umetsu , Gordon James Freeman , Tiancen Hu , John A. Taraszka , Fangmin Xu

IPC: C07K16/28 , A61K39/395 , A61K45/06

CPC classification number: C07K16/2803 , A61K39/3955 , A61K39/39558 , A61K45/06 , C07K2299/00 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N33/6893

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

Abstract translation: 公开了特异性结合TIM-3的抗体分子。抗TIM-3抗体分子可用于治疗，预防和/或诊断免疫，癌性或感染性疾病和/或病症。

4.

发明申请
METHOD OF DETECTING TIM-3 USING ANTIBODY MOLECULES TO TIM-3 有权

公开(公告)号：US20220185883A1

公开(公告)日：2022-06-16

申请号：US17484794

申请日：2021-09-24

Applicant: Novartis AG , DANA-FARBER CANCER INSTITUTE, INC. , The Children's Medical Center Corporation

Inventor： Catherine Anne Sabatos-Peyton , Barbara Brannetti , Alan S. Harris , Thomas Huber , Thomas Pietzonka , Jennifer Marie Mataraza , Walter A. Blattler , Daniel J. Hicklin , Maximiliano Vasquez , Rosemarie H. DeKruyff , Dale T. Umetsu , Gordon James Freeman , Tiancen Hu , John A. Taraszka , Fangmin Xu

IPC: C07K16/28 , G01N33/574 , A61K39/395 , A61K45/06 , G01N33/68

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

5.

发明申请
COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 有权

公开(公告)号：US20220133889A1

公开(公告)日：2022-05-05

申请号：US17478370

申请日：2021-09-17

Applicant: Novartis AG , DANA-FARBER CANCER INSTITUTE, INC. , The Children's Medical Center Corporation

Inventor： Glenn Dranoff , Catherine Anne Sabatos-Peyton , Barbara Brannetti , Alan S. Harris , Thomas Huber , Thomas Pietzonka , Jennifer Marie Mataraza , Walter A. Blattler , Daniel J. Hicklin , Maximiliano Vasquez , Rosemarie H. DeKruyff , Dale T. Umetsu , Gordon James Freeman , Tiancen Hu , John A. Taraszka , Fangmin Xu

IPC: A61K39/395 , A61K39/00 , C07K16/28 , A61P35/00 , A61K45/06

Abstract: Combination therapies comprising antibody molecules that specifically bind to TIM-3 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.

6.

发明授权
Method of detecting TIM-3 using antibody molecules to TIM-3 有权

公开(公告)号：US11155620B2

公开(公告)日：2021-10-26

申请号：US16588063

申请日：2019-09-30

Applicant: Novartis AG , DANA-FARBER CANCER INSTITUTE, INC. , Children's Medical Center Corporation

Inventor： Catherine Anne Sabatos-Peyton , Barbara Brannetti , Alan S. Harris , Thomas Huber , Thomas Pietzonka , Jennifer Marie Mataraza , Walter A. Blattler , Daniel J. Hicklin , Maximiliano Vasquez , Rosemarie H. DeKruyff , Dale T. Umetsu , Gordon James Freeman , Tiancen Hu , John A. Taraszka , Fangmin Xu

IPC: C07K16/28 , G01N33/574 , A61K39/395 , A61K45/06 , G01N33/68

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

7.

发明申请
ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF 审中-公开

公开(公告)号：US20200308277A1

公开(公告)日：2020-10-01

申请号：US16841029

申请日：2020-04-06

Applicant: Novartis AG , DANA-FARBER CANCER INSTITUTE, INC. , The Children's Medical Center Corporation

Inventor： Catherine Anne Sabatos-Peyton , Barbara Brannetti , Alan S. Harris , Thomas Huber , Thomas Pietzonka , Jennifer Marie Mataraza , Walter A. Blattler , Daniel J. Hicklin , Maximiliano Vasquez , Rosemarie H. DeKruyff , Dale T. Umetsu , Gordon James Freeman , Tiancen Hu , John A. Taraszka , Fangmin Xu

IPC: C07K16/28 , A61K39/395 , G01N33/68 , G01N33/574 , A61K45/06

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

8.

发明授权
Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory disorders 有权

公开(公告)号：US10683349B2

公开(公告)日：2020-06-16

申请号：US15906446

申请日：2018-02-27

Applicant: Novartis AG

Inventor： Franco E. Di Padova , Thomas Huber , Jean-Michel Rene Rondeau

IPC: C07K16/24 , A61K39/395 , A61K39/00

Abstract: The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17 A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17 A antagonists (inhibit the activities of IL-17 A and IL-17 AF) and are capable of inhibiting IL-17 A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL 17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.